Clearmind Medicine (CMND) Non Operating Interest Expenses (2022 - 2026)

Clearmind Medicine (CMND) has reported Non Operating Interest Expenses for 5 consecutive years, with -$190708.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Interest Expenses fell 141.11% year-over-year to -$190708.0; the trailing twelve-month figure through Jan 2026 stood at $1.1 million (down 35.03% YoY), and the FY2025 full-year result was $1.9 million, up 116.61% from the prior year.
• Non Operating Interest Expenses declined to -$190708.0 in Q1 2026 per CMND's latest filing, from $770610.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $884711.0 in Q4 2024 and bottomed at -$2.3 million in Q4 2023.
• Historically, Non Operating Interest Expenses has averaged $25661.3 across 5 years, with a median of $49361.1 in 2023.
• The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses jumped 720.86% in 2025, then sank 141.11% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at -$5107.1 in 2022, then tumbled by 45855.08% to -$2.3 million in 2023, then jumped by 137.7% to $884711.0 in 2024, then slipped by 12.9% to $770610.0 in 2025, then slumped by 124.75% to -$190708.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered -$190708.0, $770610.0, and $102430.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.